Efficacy of oryzanol combined with estradiol/estradiol and dydrogesterone in the treatment of patients with perimenopausal syndrome
Hao Junrong
Zhang Jinshan
Zhang Dandan
Huang Lin
Abstract：Objective To analyze the clinical efficacy and safety of oryzanol combined with complex packing estradiol tablets/estradiol and dydrogesterone tablets in the treatment of perimenopausal syndrome(PMS).Methods A retrospective analysis was conducted on the medical records of 180 patients with PMS who received treatment at Anyang City Cardiovascular Hospital from February 2024 to December 2024.Propensity score matching was used to exclude confounding factors such as age,disease duration,and body mass index,and a total of 90 patients were included in each group at a ratio of 1:1.The control group were treated with complex packing estradiol tablets/estradiol and dydrogesterone tablets once a day,one tablet each time.During the 28-day treatment course,one red tablet containing 1 mg of estradiol was taken orally for the first 14 days,and one yellow tablet containing 1 mg of estradiol and 10 mg of dydrogesterone was taken orally every day for the following 14 days.The observation group were treated with oryzanol tablets on the basis of the control group,one tablet each time,three times a day.The total treatment duration is 12 weeks.The clinical efficacy,bone mineral density(BMD),hormone levels and safety of the two groups before and after treatment were compared.Results The effective rate of patients in the observation group(93.33%(84/90))was higher than that in the control group(71.11%(64/90)),and the difference was statistically significant(χ2=10.140,P=0.002).After treatment,the BMD values of the lumbar spine(L1-L4)segments and bilateral femurs,as well as the estradiol levels in the observation group((1.15±0.20)g·(cm2)-1,(0.96±0.15)g·(cm2)-1,(65.74±8.25)ng·L-1,respectively)and the control group((1.09±0.19)g·(cm2)-1,(0.91±0.15)g·(cm2)-1,(54.80±7.27)ng·L-1,respectively)were higher than those before treatment in the observation group((1.02±0.12)g·(cm2)-1,(0.89±0.15)g·(cm2)-1,(39.15±5.60)ng·L-1,respectively)and the control group((1.03±0.11)g·(cm2)-1,(0.85±0.16)g·(cm2)-1,(38.90±5.59)ng·L-1,respectively),and the indicators in the observation group were higher than those in the control group(t=2.063,2.236,9.438,all P<0.05).After treatment,the levels of luteinizing hormone and follicle-stimulating hormone in the observation group((16.83±4.25)mU·mL-1,(24.09±6.32)mU·mL-1,respectively)and the control group((23.72±5.09)mU·mL-1,(38.71±7.76)mU·mL-1,respectively)were lower than those before treatment in the observation group((28.71±6.05)mU·mL-1,(45.51±9.27)mU·mL-1,re-spectively)and the control group((28.32±5.85)mU·mL-1,(45.05±9.01)mU·mL-1,respectively),and the indicators in the observation group were lower than those in the control group(t=9.857,13.859,both P<0.05).After treatment,the incidence of adverse reactions in the observation group(3.33%(3/90))was lower than that in the control group(15.56%(14/90)),and the difference was statistical-ly significant(χ2=7.860,P<0.05).Conclusion Oryzanol combined with complex packing estradiol tablets/estradiol and dydroges-terone tablets demonstrates significant clinical advantages in the treatment of PMS,which can enhance therapeutic efficacy,reduce adverse reactions,actively regulate hormone levels,and increase bone density.
Keywords：Perimenopausal syndromeOryzanolComplex packing estradiol tablets/estradiol and dydrogesterone tabletsCom-bination therapyTherapeutic efficacy
Publication Date：2025-09-25
Online Publishing Date：2025-10-10(First online date of this platform, not the publication date of the document)
Pages：5( 1099-1103 )